FAQs

Here are some answers to your frequently asked questions about BRCA testing and LYNPARZA

What is LYNPARZA?

LYNPARZA is a prescription medicine used to treat women with advanced ovarian cancer who have received previous treatment with 3 or more prior chemotherapy medicines or a combination of chemotherapy medicines for their cancer, and have a certain type of abnormal inherited BRCA gene. Your healthcare provider will perform a test to make sure that LYNPARZA is right for you.

Is LYNPARZA covered by my insurance?

Once your physician determines that you are eligible for LYNPARZA, he or she can work with the trained specialists at AstraZeneca’s Access 360 who provide access and reimbursement assistance if needed.

Is testing for a BRCA mutation covered by my insurance if I have ovarian cancer?

For women with advanced ovarian cancer, BRCA testing is covered by most insurance providers, including Medicare. Talk to your healthcare provider or insurance plan to learn about your coverage.

Is financial assistance available if I have trouble paying for LYNPARZA?

AstraZeneca offers a number of support resources, including programs for financial assistance. For more information on these programs, contact Access 360 by clicking here or by calling (844) ASKA360 (275-2360)(844) ASKA360 (275-2360).

Why do I have to have BRCA-mutated ovarian cancer to get LYNPARZA?

LYNPARZA is approved to treat patients who have BRCA-mutated advanced ovarian cancer because of the way that the drug is thought to work in BRCA-mutated cancer cells.

The only way to know whether LYNPARZA might be right for you is to be tested for the BRCA mutation.

Will my physician change my LYNPARZA dosage?

Your physician may temporarily stop treatment with LYNPARZA or change your dose of LYNPARZA if you have side effects. LYNPARZA should be taken as prescribed.

What resources are available to support me in my treatment with LYNPARZA?

My LYNPARZA is an educational program created by AstraZeneca specially for patients who are taking LYNPARZA. You can enroll in the program by either filling out the enrollment form that is included with your first LYNPARZA prescription, or calling the AstraZeneca Information Center at (800) 236-9933(800) 236-9933.

What are the risks of LYNPARZA?

LYNPARZA may cause serious side effects that can lead to death including bone marrow problems and lung problems. Some people who have ovarian cancer or who have received previous treatment with chemotherapy, radiotherapy or certain other medicines for their cancer have developed bone marrow problems called Myelodysplastic syndrome (MDS) or Acute Myeloid Leukemia (AML) during treatment with LYNPARZA. If you develop MDS or AML, your healthcare provider will stop treatment with LYNPARZA.

Symptoms of low blood cell counts are common during treatment with LYNPARZA, but can be a sign of serious bone marrow problems, including MDS or AML. Symptoms to discuss with your healthcare provider include weakness, weight loss, fever, frequent infections, blood in your urine/stool, shortness of breath, feeling very tired, and bruising or bleeding more easily.

You will undergo blood tests before, and every month during, treatment with LYNPARZA to monitor your blood cell counts. Weekly blood tests will be performed if you have low blood cell counts that last a long time. Your healthcare provider may stop treatment with LYNPARZA until your blood cell counts improve.

Tell your healthcare provider if you have any new or worsening symptoms of lung problems, including shortness of breath, fever, cough, or wheezing. Your healthcare provider may do a chest x-ray if you have any of these symptoms. Your healthcare provider may temporarily or completely stop treatment if you develop pneumonitis.

For more safety information, including common side effects, please see complete Important Safety Information below or click here.

How is LYNPARZA distributed?

LYNPARZA is available through specialty pharmacies and distributors who will mail it directly to you once prescribed by your physician.

Who can I call if I have questions about LYNPARZA?

Your physician can be a great resource for answers to your questions about LYNPARZA. You can also talk to an oncology nurse through the support line, and he or she can answer your questions about LYNPARZA. For information about the support available to you, call 1-844-ASK-A360(1-844-275-2360)1-844-ASK-A360(1-844-275-2360).

Please see complete Important Safety Information below or click here.

What are the most common side effects of LYNPARZA?

The most common side effects are anemia, nausea or vomiting, tiredness or weakness, diarrhea, indigestion or heartburn, headache, loss of appetite, changes in how food tastes, changes in kidney function blood tests, sore throat or runny nose, upper respiratory infection, cough, pain in the joints, muscles, and back, rash, and pain or discomfort in the stomach area.

LYNPARZA may cause serious side effects that can lead to death including bone marrow problems and lung problems.

For more on the side effects you might experience while taking LYNPARZA, click here.

Glossary

Improve your understanding with definitions of important terms

Learn more

BRCA Testing

Testing for BRCA1/BRCA2 mutations will help determine who may be eligible for treatment with LYNPARZA

Get the facts

INDICATION

LYNPARZA is a prescription medicine used to treat women with advanced ovarian cancer who have received previous treatment with 3 or more prior chemotherapy medicines or a combination of chemotherapy medicines for their cancer, and have a certain type of abnormal inherited BRCA gene.

Your healthcare provider will perform a test to make sure that LYNPARZA is right for you.

Please see Important Safety Information below.

IMPORTANT SAFETY INFORMATION

There are no contraindications (a condition in which the treatment should not be used) for LYNPARZA.

LYNPARZA may cause serious side effects that can lead to death including bone marrow problems and lung problems. Some people who have..Read More ovarian cancer or who have received previous treatment with chemotherapy, radiotherapy or certain other medicines for their cancer have developed bone marrow problems called Myelodysplastic syndrome (MDS) or Acute Myeloid Leukemia (AML) during treatment with LYNPARZA. If you develop MDS or AML, your healthcare provider will stop treatment with LYNPARZA.

Symptoms of low blood cell counts are common during treatment with LYNPARZA, but can be a sign of serious bone marrow problems, including MDS or AML. Symptoms to discuss with your healthcare provider include weakness, weight loss, fever, frequent infections, blood in your urine/stool, shortness of breath, feeling very tired, and bruising or bleeding more easily.

You will undergo blood tests before, and every month during, treatment with LYNPARZA to monitor your blood cell counts. Weekly blood tests will be performed if you have low blood cell counts that last a long time. Your healthcare provider may stop treatment with LYNPARZA until your blood cell counts improve.

Tell your healthcare provider if you have any new or worsening symptoms of lung problems, including shortness of breath, fever, cough, or wheezing. Your healthcare provider may do a chest x-ray if you have any of these symptoms. Your healthcare provider may temporarily or completely stop treatment if you develop pneumonitis (inflammation of the lungs).

Before you take LYNPARZA, tell your healthcare provider about all of your medical conditions including:

  • lung or breathing problems
  • liver problems
  • kidney problems
  • are pregnant or plan to become pregnant. LYNPARZA can harm your unborn baby and may cause loss of pregnancy (miscarriage).
    • If you are able to become pregnant, your healthcare provider may do a pregnancy test before you start treatment with LYNPARZA.
    • Females who are able to become pregnant should use effective birth control (contraception) during treatment with LYNPARZA and for 6 months after receiving the last dose of LYNPARZA.
    • Talk to your healthcare provider about birth control methods that may be right for you.
    • Tell your healthcare provider right away if you become pregnant.
  • are breastfeeding or plan to breastfeed. It is not known if LYNPARZA passes into your breast milk. Do not breastfeed during treatment and for 1 month after receiving the last dose of LYNPARZA. Talk to your healthcare provider about the best way to feed your baby.

Avoid grapefruit, grapefruit juice and Seville oranges during treatment as they may increase the levels of LYNPARZA in your blood.

The most common side effects are anemia, nausea or vomiting, tiredness or weakness, diarrhea, indigestion or heartburn, headache, loss of appetite, changes in how food tastes, changes in kidney function blood tests, sore throat or runny nose, upper respiratory infection, cough, pain in the joints, muscles, and back, rash, and pain or discomfort in the stomach area.

These are not all the possible side effects of LYNPARZA. For more information, ask your healthcare provider or pharmacist.

Call your healthcare provider for medical advice about side effects.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.FDA.gov/medwatch or call 1-800-FDA-1088 1-800-FDA-1088.

Please see complete Prescribing Information, including Patient Information (Medication Guide).

The information on this Web site should not take the place of talking with your doctor or healthcare professional. If you have any questions about your condition, or if you would like more information about LYNPARZA, talk to your doctor or pharmacist. Only you and your healthcare professional can decide if LYNPARZA is right for you.